Jennifer Mullins, APRN
Psychiatric/Mental Health · Erlanger, KYNPI 1174063234
Payments from drug & device makers
Across 125 payments — averaging $30.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$708
- Axsome Therapeutics, Inc.$458
- Otsuka America Pharmaceutical, Inc.$336
- Acadia Pharmaceuticals Inc$316
- Lundbeck LLC$315
- plus $540 from 11 others
What the payments were for
- Food & beverage$3,81599%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 38 | $1,174 |
| AbbVie | 19 | $708 |
| Axsome Therapeutics, Inc. | 5 | $458 |
| Otsuka America Pharmaceutical, Inc. | 13 | $336 |
| Acadia Pharmaceuticals Inc | 7 | $316 |
| Lundbeck LLC | 19 | $315 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $118 |
| Noven Therapeutics, LLC | 5 | $102 |
| Idorsia Pharmaceuticals US Inc | 1 | $89 |
| Alkermes, Inc. | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| Luye Pharma (USA) Ltd. | 2 | $44 |
| Indivior Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Bioxcel Therapeutics, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$359
- Auvelity$341
- NUPLAZID$269
- VRAYLAR$125
- UZEDY$123
How this compares
$3,847 in reported general payments places this provider in the 85th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 26 | $20,023 |
| Olanzapine | 36 | $1,533 |
| Risperidone | 44 | $568 |
| Quetiapine Fumarate | 19 | $418 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $348 |
| Fluoxetine Hcl | 26 | $323 |
| Pravastatin Sodium | 12 | $320 |
| Prazosin Hcl | 18 | $284 |
| Buspirone Hcl | 16 | $268 |
| Memantine Hcl | 27 | $249 |
| Rosuvastatin Calcium | 14 | $218 |
| Levothyroxine Sodium | 17 | $209 |
| Mirtazapine | 17 | $195 |
| Losartan Potassium | 20 | $187 |
| Benztropine Mesylate | 13 | $179 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Erlanger
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
- Hope SmithHopkinsville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.